VEGFA and neoplasm: In this setting, TKIs have been proposed due to their capability of targeting angiogenesis and tumour-spreading processes as MCC expresses VEGF-A, VEGF-C, VEGF-R2, and platelet-derived growth factor (PDGF)-b in 91, 75, 88 and 72%, respectively [50, 51].